UK RPM OTC Action Moving Forward?

24 September 1997

While the UK Director General of Fair Trading had not last week appliedto the Restrictive Practices Court to begin the process of seeking to end Resale Price Maintenance on over-the-counter medicines, a spokesman for the Office of Fair Trading told the Marketletter that he believed such a move to be "fairly close."

Discussing speculation that submission of the application was imminent, the spokesman said no date had yet been set but indicated that this could change within a week or two. DGFT John Bridgeman first announced his intention to begin legal action to end RSM on OTCs almost a year ago (Marketletter October 28, 1996).

Speculation concerning the OFT's intentions is widespread and varied. A spokeswoman for the Community Pharmacy Action Group, which is fighting the proposals, told the Marketletter that while other observers believed that the Office was having trouble assembling evidence for its case, some felt it was delaying proceedings because of the publication of the government's draft Competition Bill.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight